Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(57.1%)

N/A

3(42.9%)

7Total

Phase 2(4)

N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06174519Completed

Evaluation of the Artificial Intelligence-based Prescription Support Software iAST® for the Choice of Empirical and Semi-targeted Antibiotic Treatment

Role: collaborator

NCT01703910Phase 2Completed

Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic

Role: collaborator

NCT01454180Phase 2Completed

Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets

Role: collaborator

NCT02075086Phase 2Unknown

Angiogenic Switch in Patients With Colorectal Cancer

Role: lead

NCT02231970Not ApplicableUnknown

Endoscopic Sleeve Gastroplasty for Treatment of Obesity

Role: lead

NCT01442974Not ApplicableCompleted

Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer

Role: lead

NCT01453257Phase 2Completed

Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients

Role: lead

NCT01366118Not ApplicableCompleted

Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients

Role: lead

All 8 trials loaded